ERBB2 and breast cancer: miR-221 is an additional microRNA molecule that promotes trastuzumab resistance and metastasis in HER2+ BC, evincing its potential as a predictive biomarker for HER2-targeted therapy resistance and as a novel target for anti-HER2 combination therapy [169].